Skip to main content Accessibility help
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2011
  • Online publication date: December 2011

31 - Dimethyl fumarate to treat multiple sclerosis

from Section III - Clinical trials of multiple sclerosis therapies


This chapter lists the factors that differentiate pharmacogenomics from conventional biomarker research on a strategic, operational, and technical level. The "-omics" technologies and conventional methods are mutually complementary approaches in the search for biomarkers. The genetic component of multiple sclerosis (MS) risk has been the focus of study for a long time, and beyond the classic association with the MHC locus, seven genome-wide association studies (GWAS) reported in recent years have helped identify other candidate genes, such as the IL-7 and IL-2 receptors. Compared with DNA- and RNA-based analyses, proteomics and metabolomics are less advanced techniques. The requirements for establishing a comprehensive and integrated matrix of genotype/phenotype interaction are: development of technologies for proteomics and metabolomics to the same level as genotyping and trancriptomics, development of bioinformatic tools, and development of longitudinally studied cohorts characterized using standardized, high-quality clinical and paraclinical methods.


1. Schweckendiek W. [Treatment of psoriasis vulgaris]. Med Monatsschr. 1959; 13:103–4.
2. Balasubramaniam P, Stevenson O, Berth-Jones J. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities. Br J Dermatol 2004; 150:741–746.
3. Ormerod AD, Mrowietz U. Fumaric acid esters, their place in the treatment of psoriasis. Br J Dermatol 2004; 150:630–2.
4. Altmeyer PJ, Matthes U, Pawlak F, et al. Antipsoriatic effect of fumaric acid derivatives. Results of a multicenter double-blind study in 100 patients. J Am Acad Dermatol 1994; 30:977–81.
5. de Jong R, Bezemer AC, Zomerdijk TP, van de Pouw-Kraan T, Ottenhoff TH, Nibbering PH. Selective stimulation of T helper 2 cytokine responses by the anti-psoriasis agent monomethylfumarate. Eur J Immunol 1996; 26:2067–74.
6. Schimrigk S, Brune N, Hellwig K, et al. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol 2006; 13:604–10.
7. Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003; 121:1383–8.
8. Sebok B, Bonnekoh B, Geisel J, Mahrle G. Antiproliferative and cytotoxic profiles of antipsoriatic fumaric acid derivatives in keratinocyte cultures. Eur J Pharmacol 1994; 270:79–87.
9. Sebok B, Bonnekoh B, Vetter R, Schneider I, Gollnick H, Mahrle G. The antipsoriatic dimethyl-fumarate suppresses interferon-gamma -induced ICAM-1 and HLA-DR expression on hyperproliferative keratinocytes. Quantification by a culture plate-directed APAAP-ELISA technique. Eur J Dermatol 1998; 8:29–32.
10. Risch K, Strebel HP, Joshi RK, et al. Methyl hydrogen fumarate inhibits acute and chronic rejection in rat kidney transplantation models. Transpl Proc 2001; 33:545–6.
11. Lehmann M, Risch K, Nizze H, et al. Fumaric acid esters are potent immunosuppressants: inhibition of acute and chronic rejection in rat kidney transplantation models by methyl hydrogen fumarate. Arch Dermatol Res 2002; 294:399–404.
12. Loewe R, Holnthoner W, Groger M, et al. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 2002; 168:4781–7.
13. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain 2011; 134:678–92.
14. Kappos L, Gold R, Miller DH, et al. Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet 2008; 372:1463–72.
15. Stoof TJ, Flier J, Sampat S, Nieboer C, Tensen CP, Boorsma DM. The antipsoriatic drug dimethylfumarate strongly suppresses chemokine production in human keratinocytes and peripheral blood mononuclear cells. Br J Dermatol 2001; 144:1114–20.
16. Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006; 129:1953–71.
17. Schilling S, Goelz S, Linker R, Luehder F, Gold R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 2006; 145:101–7.
18. Filippi M, Cercignani M, Inglese M, Horsfield MA, Comi G. Diffusion tensor magnetic resonance imaging in multiple sclerosis. Neurology 2001; 56:304–11.
19. Dalton CM, Miszkiel KA, Barker GJ, MacManus DG, Pepple TI, Panzara M, et al. Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis. J Neurol 2004; 251:407–13.
20. Macmanus DG, Miller DH, Kappos L, et al. BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis. J Neurol 2010 Epub Oct 21.